• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

炎症性肺病患儿的表面活性剂含量

Surfactant content in children with inflammatory lung disease.

作者信息

LeVine A M, Lotze A, Stanley S, Stroud C, O'Donnell R, Whitsett J, Pollack M M

机构信息

Section of Critical Care Medicine, Children's National Medical Center, Washington, DC, USA.

出版信息

Crit Care Med. 1996 Jun;24(6):1062-7. doi: 10.1097/00003246-199606000-00029.

DOI:10.1097/00003246-199606000-00029
PMID:8681574
Abstract

OBJECTIVE

To determine surfactant profiles of tracheal secretions in mechanically ventilated children with respiratory failure secondary to bacterial pneumonia, viral pneumonitis, adult respiratory distress syndrome (ARDS), and cardiopulmonary bypass.

DESIGN

Prospective, cohort study.

SETTING

Tertiary, multidisciplinary, pediatric intensive care unit.

PATIENTS

One hundred twenty pediatric patients with respiratory failure requiring mechanical ventilation.

INTERVENTIONS

Routine tracheal aspirates were collected from children with bacterial pneumonia, viral pneumonitis, ARDS, postcardiopulmonary bypass, and a postsurgical control group. Samples were obtained on days 1, 2, 3, after every week of intubation and on the day of extubation.

MEASUREMENTS AND MAIN RESULTS

The tracheal aspirates were analyzed by high-performance liquid chromatography for lecithin/sphingomyelin rations and by enzyme-linked immunosorbent assay for surfactant proteins A and B. Lung compliance and the oxygenation index were measured on each day of sample collection. On day 1, patients with bacterial pneumonia, viral pneumonitis, and ARDS had decreased lecithin/sphingomyelin ration (p < .001), and those patients with bacterial pneumonia and viral pneumonitis had decreased surfactant protein A/protein concentration (p < .001). The lecithin/sphingomyelin ratios and surfactant protein A/protein concentration were significantly different among the groups (p < .001), with the bacterial pneumonia and viral pneumonitis groups having higher lecithin/sphingomyelin ratios and increased surfactant protein concentrations before extubation. Pulmonary compliance was lower and the oxygenation index was higher than controls (p < .001) in patients with bacterial pneumonia, viral pneumonitis, and ARDS. Pulmonary compliance was correlated weakly with lecithin/sphingomyelin ratio (r2 = .11, p < .001) and surfactant protein A/protein concentration (r2 = .03, p < .05). Surfactant protein B was similar in the diagnostic groups. Surfactant content in tracheal secretions from cardiopulmonary bypass patients was equivalent to controls.

CONCLUSION

Abnormal tracheal aspirate surfactant phospholipids and surfactant protein A were noted in children with bacterial pneumonia, viral pneumonitis, and ARDS, but not in children on cardiopulmonary bypass.

摘要

目的

确定继发于细菌性肺炎、病毒性肺炎、成人呼吸窘迫综合征(ARDS)和体外循环的呼吸衰竭的机械通气儿童气管分泌物中的表面活性剂谱。

设计

前瞻性队列研究。

地点

三级多学科儿科重症监护病房。

患者

120例需要机械通气的呼吸衰竭儿科患者。

干预措施

从患有细菌性肺炎、病毒性肺炎、ARDS、体外循环术后的儿童以及术后对照组收集常规气管吸出物。在插管后的第1天、第2天、第3天、每周后以及拔管当天采集样本。

测量指标及主要结果

通过高效液相色谱法分析气管吸出物中的卵磷脂/鞘磷脂比值,通过酶联免疫吸附测定法分析表面活性剂蛋白A和B。在采集样本的每一天测量肺顺应性和氧合指数。第1天,患有细菌性肺炎、病毒性肺炎和ARDS的患者卵磷脂/鞘磷脂比值降低(p < .001),患有细菌性肺炎和病毒性肺炎的患者表面活性剂蛋白A/蛋白浓度降低(p < .001)。各组之间卵磷脂/鞘磷脂比值和表面活性剂蛋白A/蛋白浓度存在显著差异(p < .001),细菌性肺炎和病毒性肺炎组在拔管前卵磷脂/鞘磷脂比值更高且表面活性剂蛋白浓度增加。细菌性肺炎、病毒性肺炎和ARDS患者的肺顺应性低于对照组,氧合指数高于对照组(p < .001)。肺顺应性与卵磷脂/鞘磷脂比值(r2 = .11,p < .001)和表面活性剂蛋白A/蛋白浓度(r2 = .03,p < .05)弱相关。表面活性剂蛋白B在各诊断组中相似。体外循环患者气管分泌物中的表面活性剂含量与对照组相当。

结论

在患有细菌性肺炎、病毒性肺炎和ARDS的儿童中发现气管吸出物表面活性剂磷脂和表面活性剂蛋白A异常,但体外循环儿童未出现异常。

相似文献

1
Surfactant content in children with inflammatory lung disease.炎症性肺病患儿的表面活性剂含量
Crit Care Med. 1996 Jun;24(6):1062-7. doi: 10.1097/00003246-199606000-00029.
2
Changes in biochemical and biophysical surfactant properties with cardiopulmonary bypass in children.小儿体外循环期间生化及生物物理表面活性物质特性的变化
Crit Care Med. 2003 Jan;31(1):284-90. doi: 10.1097/00003246-200301000-00045.
3
Serial lecithin/sphingomyelin ratios and surfactant/albumin ratios in tracheal aspirates from term infants with respiratory failure receiving extracorporeal membrane oxygenation.接受体外膜肺氧合治疗的足月呼吸衰竭婴儿气管吸出物中卵磷脂/鞘磷脂比值及表面活性剂/白蛋白比值的系列研究
Clin Chem. 1995 Aug;41(8 Pt 1):1182-8.
4
Phospholipid and surfactant protein A concentrations in tracheal aspirates from infants requiring extracorporeal membrane oxygenation.需要体外膜肺氧合治疗的婴儿气管吸出物中的磷脂和表面活性蛋白A浓度
J Pediatr. 1992 Aug;121(2):271-4. doi: 10.1016/s0022-3476(05)81202-8.
5
Pulmonary surfactant in patients with Pneumocystis pneumonia and acquired immunodeficiency syndrome.卡氏肺孢子虫肺炎和获得性免疫缺陷综合征患者的肺表面活性物质
Crit Care Med. 2006 Sep;34(9):2370-6. doi: 10.1097/01.CCM.0000234036.19145.52.
6
Clinical experience of extracorporeal membrane oxygenation for acute respiratory distress syndrome associated with pneumonia in children.儿童肺炎相关性急性呼吸窘迫综合征体外膜肺氧合的临床经验。
J Formos Med Assoc. 2012 Mar;111(3):147-52. doi: 10.1016/j.jfma.2011.01.006. Epub 2012 Feb 22.
7
Surfactant phospholipids, surfactant proteins, and inflammatory markers during acute lung injury in children.儿童急性肺损伤时的表面活性剂磷脂、表面活性剂蛋白和炎症标志物。
Pediatr Crit Care Med. 2010 Jan;11(1):82-91. doi: 10.1097/PCC.0b013e3181ae5a4c.
8
A shared protocol for porcine surfactant use in pediatric acute respiratory distress syndrome: a feasibility study.儿科急性呼吸窘迫综合征中猪肺表面活性剂使用的共享方案:一项可行性研究。
BMC Pediatr. 2019 Jun 18;19(1):203. doi: 10.1186/s12887-019-1579-3.
9
Improved pulmonary outcome after exogenous surfactant therapy for respiratory failure in term infants requiring extracorporeal membrane oxygenation.对于需要体外膜肺氧合的足月儿呼吸衰竭,外源性表面活性剂治疗后肺部结局改善。
J Pediatr. 1993 Feb;122(2):261-8. doi: 10.1016/s0022-3476(06)80131-9.
10
Instillation of calf lung surfactant extract (calfactant) is beneficial in pediatric acute hypoxemic respiratory failure. Members of the Mid-Atlantic Pediatric Critical Care Network.滴注小牛肺表面活性物质提取物(calfactant)对小儿急性低氧性呼吸衰竭有益。大西洋中部儿科重症监护网络成员。
Crit Care Med. 1999 Jan;27(1):188-95. doi: 10.1097/00003246-199901000-00050.

引用本文的文献

1
Revisiting the role of pulmonary surfactant in chronic inflammatory lung diseases and environmental exposure.重新审视肺表面活性剂在慢性炎症性肺疾病和环境暴露中的作用。
Eur Respir Rev. 2021 Dec 15;30(162). doi: 10.1183/16000617.0077-2021. Print 2021 Dec 31.
2
Surfactant phospholipids act as molecular switches for premature induction of quorum sensing-dependent virulence in .表面活性剂磷脂作为分子开关,可提前诱导依赖群体感应的毒力。
Virulence. 2020 Dec;11(1):1090-1107. doi: 10.1080/21505594.2020.1809327.
3
Rational use of mucoactive medications to treat pediatric airway disease.
合理使用黏液促排药物治疗儿科气道疾病。
Paediatr Respir Rev. 2020 Nov;36:8-14. doi: 10.1016/j.prrv.2020.06.007. Epub 2020 Jun 16.
4
Lung Infection Results in Down-Regulation of Surfactant Protein-A Mainly Caused by Pro-Inflammatory Macrophages.肺部感染导致表面活性蛋白A下调,主要由促炎性巨噬细胞引起。
Microorganisms. 2020 Apr 16;8(4):577. doi: 10.3390/microorganisms8040577.
5
Role of Inhaled Nitric Oxide in the Management of Severe Acute Respiratory Distress Syndrome.吸入一氧化氮在治疗严重急性呼吸窘迫综合征中的作用。
Front Pediatr. 2016 Aug 2;4:74. doi: 10.3389/fped.2016.00074. eCollection 2016.
6
Biomarkers in Pediatric ARDS: Future Directions.儿科急性呼吸窘迫综合征的生物标志物:未来方向。
Front Pediatr. 2016 Jun 1;4:55. doi: 10.3389/fped.2016.00055. eCollection 2016.
7
Surfactant Administration During Pediatric Extracorporeal Membrane Oxygenation.小儿体外膜肺氧合期间的表面活性剂给药
ASAIO J. 2015 Nov-Dec;61(6):682-7. doi: 10.1097/MAT.0000000000000266.
8
Surfactant protein B and A concentrations are increased in neonatal pneumonia.新生儿肺炎时表面活性蛋白B和A的浓度会升高。
Pediatr Res. 2015 Oct;78(4):401-6. doi: 10.1038/pr.2015.123. Epub 2015 Jun 24.
9
Increased surfactant protein D fails to improve bacterial clearance and inflammation in serpinB1-/- mice.Surfactant protein D 增加未能改善 serp inB1-/- 小鼠的细菌清除和炎症反应。
Am J Respir Cell Mol Biol. 2012 Dec;47(6):792-9. doi: 10.1165/rcmb.2012-0145OC. Epub 2012 Sep 28.
10
Surfactant for bacterial pneumonia in late preterm and term infants.用于晚期早产儿和足月儿细菌性肺炎的表面活性剂
Cochrane Database Syst Rev. 2012 Feb 15;2012(2):CD008155. doi: 10.1002/14651858.CD008155.pub2.